Chris Schott
Stock Analyst at JP Morgan
(3.61)
# 850
Out of 5,032 analysts
141
Total ratings
58.33%
Success rate
3.86%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $21.42 | +12.04% | 4 | Oct 7, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $23 → $26 | $19.31 | +34.65% | 18 | Oct 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $135 → $145 | $122.81 | +18.07% | 7 | Sep 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,100 → $1,050 | $802.83 | +30.79% | 22 | Sep 16, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $9.92 | +41.13% | 3 | Sep 16, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $235 | $229.57 | +2.37% | 3 | Sep 16, 2025 | |
| PRGO Perrigo Company | Maintains: Overweight | $38 → $35 | $21.62 | +61.89% | 12 | Aug 7, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $550 → $675 | $635.40 | +6.23% | 8 | Aug 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $578.05 | +38.40% | 8 | Jun 9, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $143.00 | +22.38% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $230 | $144.06 | +59.66% | 2 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $20 | $9.28 | +115.52% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $37.01 | +13.48% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $298.81 | -9.64% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.51 | +38.72% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $84.79 | +47.42% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $10.17 | +37.66% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.65 | +566.67% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.05 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $43.63 | +78.78% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $1.31 | +72,419.08% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.25 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $22.86 | +118.72% | 3 | Nov 2, 2018 |
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $21.42
Upside: +12.04%
Teva Pharmaceutical Industries
Oct 3, 2025
Maintains: Overweight
Price Target: $23 → $26
Current: $19.31
Upside: +34.65%
Gilead Sciences
Sep 16, 2025
Maintains: Overweight
Price Target: $135 → $145
Current: $122.81
Upside: +18.07%
Eli Lilly and Company
Sep 16, 2025
Maintains: Overweight
Price Target: $1,100 → $1,050
Current: $802.83
Upside: +30.79%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $9.92
Upside: +41.13%
AbbVie
Sep 16, 2025
Maintains: Overweight
Price Target: $200 → $235
Current: $229.57
Upside: +2.37%
Perrigo Company
Aug 7, 2025
Maintains: Overweight
Price Target: $38 → $35
Current: $21.62
Upside: +61.89%
IDEXX Laboratories
Aug 4, 2025
Maintains: Overweight
Price Target: $550 → $675
Current: $635.40
Upside: +6.23%
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $578.05
Upside: +38.40%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $143.00
Upside: +22.38%
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $144.06
Upside: +59.66%
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.28
Upside: +115.52%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $37.01
Upside: +13.48%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $298.81
Upside: -9.64%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.51
Upside: +38.72%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $84.79
Upside: +47.42%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $10.17
Upside: +37.66%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.65
Upside: +566.67%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.05
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $43.63
Upside: +78.78%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $1.31
Upside: +72,419.08%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $22.86
Upside: +118.72%